Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALMS

Alumis Inc.

Sep 18 • 04:00PM ET

11.34

Dollar change +0.73
Percentage change 6.88	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	50.18%	Shs Outstand	44.66M	Perf Week	3.75%
Market Cap	535.47M	Forward P/E	-	EPS next Y	-	Insider Trans	46.31%	Shs Float	23.53M	Perf Month	-12.77%
Income	-	PEG	-	EPS next Q	-1.31	Inst Own	34.19%	Short Float	5.45%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	7.47	Perf Half Y	-
Book/sh	-8.06	P/B	-	EPS next Y	-	ROA	-	Short Interest	1.28M	Perf Year	-
Cash/sh	4.44	P/C	2.55	EPS next 5Y	-	ROE	-	52W Range	10.37 - 13.53	Perf YTD	-14.74%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-16.19%	Beta	-
Dividend TTM	-	Quick Ratio	6.73	Sales past 5Y	0.00%	Gross Margin	-	52W Low	9.35%	ATR (14)	0.80
Dividend Ex-Date	-	Current Ratio	6.73	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	43.09	Volatility	9.23% 6.10%
Employees	-	Debt/Eq	0.16	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	32.33
Option/Short	No / Yes	LT Debt/Eq	0.15	EPS Q/Q	-	Payout	-	Rel Volume	1.32	Prev Close	10.61
Sales Surprise	-	EPS Surprise	14.04%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	171.68K	Price	11.34
SMA20	-6.32%	SMA50	-7.51%	SMA200	-7.52%	Trades		Volume	225,774	Change	6.88%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Initiated	Morgan Stanley	Overweight	$36
Jul-23-24	Initiated	Leerink Partners	Outperform	$29
Jul-23-24	Initiated	Guggenheim	Buy	$32
Jul-23-24	Initiated	Cantor Fitzgerald	Overweight

Sep-03-24 04:29PM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements (GlobeNewswire)
Jul-29-24 08:00AM	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Jun-27-24 11:57PM	Alumis Announces Pricing of Initial Public Offering (GlobeNewswire)

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foresite Labs, LLC	10% Owner	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:31 PM
Foresite Capital Management V,	10% Owner	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:30 PM
Tananbaum James B.	Director	Jul 01 '24	Buy	16.00	2,500,000	40,000,000	5,584,889	Jul 03 09:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALMS

Alumis Inc.

Upgrade your FINVIZ experience